Cargando…
SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
Globally, diabetes mellitus is a leading cause of kidney disease, with a critical percent of patients approaching end-stage kidney disease. In the current era, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as phenomenal agents in halting the progression of kidney disease. Positive...
Autores principales: | Kanduri, Swetha R., Kovvuru, Karthik, Hansrivijit, Panupong, Thongprayoon, Charat, Vallabhajosyula, Saraschandra, Pivovarova, Aleksandra I., Chewcharat, Api, Garla, Vishnu, Medaura, Juan, Cheungpasitporn, Wisit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564486/ https://www.ncbi.nlm.nih.gov/pubmed/32846935 http://dx.doi.org/10.3390/jcm9092723 |
Ejemplares similares
-
Kidney Recovery From Acute Kidney Injury After Hematopoietic Stem Cell Transplant: A Systematic Review and Meta-Analysis
por: Kanduri, Swetha Rani, et al.
Publicado: (2021) -
Efficacy and Safety of SGLT-2 Inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis
por: Chewcharat, Api, et al.
Publicado: (2020) -
Treatment of C3 Glomerulopathy in Adult Kidney Transplant Recipients: A Systematic Review
por: Gonzalez Suarez, Maria L, et al.
Publicado: (2020) -
Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients
por: Thongprayoon, Charat, et al.
Publicado: (2020) -
Promises of Big Data and Artificial Intelligence in Nephrology and Transplantation
por: Thongprayoon, Charat, et al.
Publicado: (2020)